[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"appendiceal-mucinous-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:appendiceal-mucinous-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054012","phase-2-metformin-in-pseudomyxoma-peritonei-secondary-to-appendiceal-mucinous-neoplasms-100054012",false,"NCT07693452","Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Key Inclusion Criteria (complete details available in protocol):\n\n* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent\u002Frefractory disease s\u002Fp cytoreductive surgery(CRS)\u002Fhyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS\u002FHIPEC\n* Age ≥18 years\n* ECOG performance status ≤2\n\nKey Exclusion Criteria (complete details available in protocol):\n\n* Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS\u002FHIPEC\n* Patients currently taking metformin for another medical indication\n* Patients with a prior adverse event to administration of metformin","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).",[26,27],"Appendiceal Mucinous Neoplasm","Pseudomyxoma Peritonei",[26,27,29,30,31,32],"Pseudomyxoma Peritoneal","PMP","AMNs","Metformin","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-06-18",{"date":41,"type":20},"2029-07",{"name":43,"class":44},"University of California, Irvine","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":74,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":45},"100495686","genetics-of-appendix-cancer-study-100495686","NCT05734430","Genetics of Appendix Cancer Study","Genetics of Appendix Cancer: The GAP Study","GAP","Inclusion Criteria:\n\nGAP Social\n\n* Known diagnosis of appendix cancer in the United States\n* Mentally and physically able to consent and participate in the study\n\nGAP Vanderbilt\n\n* Known diagnosis of appendix cancer\n* Diagnosed by and\u002For consulting with a physician\u002Fclinical provider participating in the GAP Study\n* Mentally and physically able to consent and participate in the study\n\nGAP Parent\n\n* Biological parents (mother and\u002For father) of individuals actively participating in the GAP Study\n* Residing in the United States\n* Mentally and physically able to consent and participate in the study\n\nExclusion Criteria:\n\n* Women pregnant at the time of consent\n* Prisoners\n* Unable to provide informed consent\n* Unable to read, write, or complete questionnaires in English",true,{"count":56,"type":20},700,"OBSERVATIONAL","The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix\u002Fappendiceal cancer who are ages 18+ years.",[60,61,62,26,63,64,65,66,67,68,69,70,71,72,73],"Appendix Cancer","Appendiceal Cancer","Appendiceal Neoplasms","Appendiceal Adenocarcinoma","Appendiceal Carcinoid Tumor","Appendiceal Neoplasm Malignant Secondary","Appendix Adenocarcinoma","Appendix Mucinous Neoplasm","Appendix Tumor","Appendix Cancer Metastatic","Appendix NET","Low-Grade Appendix Mucinous Neoplasm","High Grade Appendix Mucinous Neoplasm","High Grade Appendix Mucinous Adenocarcinoma",[75],"Genetics","2025-04-15",{"date":78,"type":37},"2025-04-18",{"date":80,"type":37},"2022-11-11",{"date":82,"type":20},"2034-11",{"name":84,"class":44},"Andreana Holowatyj, PhD, MSCI"]